BACKGROUND
Primary bladder amyloidosis assumes clinical importance as it clinically masquerades as a malignancy as in the case presented. Isolated bladder amyloidosis is most frequent in the fi fth and sixth decade. It has equal sex preponderance. Histological diagnosis is essential. Recurrence rates postresection is estimated at 50%.
CASE PRESENTATION
A 69-year-old lady was referred to the urology outpatient with an 18-month history of intermittent frank painless haematuria. There was no associated lower urinary tract or constitutional symptoms. Medical history was positive for hypertension, hypercholesterolemia and gastro-oesophageal refl ux disease. Her regular medications included aspirin, atacand, lipostat and omeprazole. She had no known drug allergies. Surgical history included appendicectomy, hysterectomy, oophorectomy and cystocoele repair. There was no signifi cant family history. She was a non-smoker. Clinical examination revealed no signifi cant abnormality. 
INVESTIGATIONS

Summary
Primary localised bladder amyloidosis is a very rare entity, with only 200 cases reported worldwide. Our case illustrates the classical presentation of isolated bladder amyloidosis with frank painless haematuria and irritative voiding symptoms. showed an unusual appearance of the urinary bladder with markedly enlarged pelvic veins. There was no associated perivesical lymphadenopathy. Cystoscopy revealed a haemorrhagic oedematous patch on the left lateral sidewall of the bladder.
DIFFERENTIAL DIAGNOSIS
Neoplasia, lymphoma and haemorrhagic cystitis were among the differentials.
TREATMENT
A transurethral resection was performed. Pathology showed no evidence of cancer. Staining with alkaline Congo red revealed a salmon pink appearance. Apple green birefringence was detected under polarised light ( fi gure 1 ). No staining was identifi ed at immunohistochemistry using monospecifi c antibodies reactive with serum amyloid A protein ,transthyretin ,apolipoprotein A1 or, with κ-and λ-immunoglobulin light chains. The amyloid did not stain with any of these antibodies.
OUTCOME AND FOLLOW-UP
She was diagnosed with primary amyloidosis of the bladder. Her haematuria resolved. She shall be followed by yearly surveillance cystoscopy.
DISCUSSION
Amyloidosis is characterised by the extracellular deposition of proteins. Amyloidosis may be primary or secondary depending on whether it is due to underlying immune dyscrasia or secondary to a chronic infl ammatory disorder. While systemic amyloid can occur anywhere in the urinary tract, including the kidney, renal pelvis, ureter, urethra or corpora, primary localised bladder amyloidosis is a rare urological disease with approximately 200 cases reported in the literature. 1 -3 Chronic cystitis and infl ammation lead to the synthesis and accumulation of miss folded amyloid precursor protein, particularly light chain immunoglobulin protein. 4 Bladder amyloidosis affects males and females equally in about the fi fth and sixth decades of life. The classical presentation with primary bladder amyloidosis is gross painless haematuria (60%), irritative voiding symptoms (20%) or both (20%). 1 -3 Primary bladder amyloidosis assumes clinical importance as it clinically masquerades as a malignancy as in the case presented.
The cystoscopic appearance can often puzzle the clinician with carcinoma and interstitial cystitis the competing differentials in most cases. Deposits vary from multiple yellow plaques to multiple ulcerated polypoid masses to diffuse irregular thickening of the bladder wall. It is for this reason that histological evaluation is essential for diagnosis. Histologically, as in our case, the diagnosis is confi rmed by the presence of fl uorescent apple green birefringence after Congo red staining and visualisation of the specimen under polarised light. The composition of the amyloid can be demonstrated immunohistochemically. AL and AA amyloid deposits can be distinguished to some extent histochemically by treating with potassium permanganate (KMNO 4 ).
Typically primary amyloidosis deposits superfi cially beneath the surface mucosa sometimes extending into the superfi cial smooth muscle of the urinary bladder. In secondary amyloidosis, the amyloid tends to accumulate in the bladder vasculature thus explaining why secondary amyloidosis with diffuse bladder involvement has a high mortality of 30% with its potential for massive haemorrhage. 5 As demonstrated in our case, transurethral resection is the treatment of choice with primary bladder amyloidosis. Medical treatments such as intravesical dimethyl sulfoxide installation and oral colchicines have also been tried with limited success.
Recurrence rates postresection is estimated to be around 50%. 6 Recurrence warrants full reassessment as cases of coexistent malignancy have been reported. 4 While no official guidelines exist for surveillance, most centers would advocate follow-up cystoscopy at 1-3 year intervals. 
Learning points
